CMS kicks off 9-month process on whether to limit coverage to Biogen's new Alzheimer's drug
The Centers for Medicare & Medicaid Services late Monday opened a formal process, rarely done for new therapeutics, to carefully review whether it will limit …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
